The study shows that Adjuvant EGFR-TKI (gefitinib) leads to significantly longer disease-free survival with lower toxicity and better improvement of quality of life compared with that for vinorelbine plus cisplatin in Chinese patients with completely resected, stage II-IIIA, EGFR-mutant NSCLC [95]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.